<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="migraine/PMC6771736/results/search/funders/results.xml">
  <result pre="Heart Defects, Center for Pediatrics University Hospital Heidelberg Germany [3]," exact="Children's Hospital Colorado," post="Heart Institute University of Colorado School of Medicine Denver"/>
  <result pre="Germany [3], Children's Hospital Colorado, Heart Institute University of Colorado" exact="School of Medicine" post="Denver Colorado [4], Cardiology Department Great Ormond Street Hospital"/>
  <result pre="of Colorado School of Medicine Denver Colorado [4], Cardiology Department" exact="Great Ormond Street Hospital for Children" post="NHS Foundation Trust London UK [5], M3C‐Paediatric Cardiology, Necker"/>
  <result pre="Trust London UK [5], M3C‐Paediatric Cardiology, Necker Enfants Malades, AP‐HP" exact="Université Paris Descartes" post="Paris France * Correspondence Maurice Beghetti MD, Pediatric Cardiology"/>
  <result pre="strategy for pediatric PAH. PAH pediatrics riociguat sGC stimulators Funding" exact="Bayer" post="AG, Berlin, Germany fig-count: table-count: page-count: word-count: Beghetti M"/>
  <result pre="disease EMA European Medicines Agency ERAs Endothelin receptor antagonists FDA" exact="Food and Drug Administration" post="iPAH Idiopathic PAH mPAP Mean pulmonary artery pressure NO"/>
  <result pre="sGC Soluble guanylate cyclase tid Three times daily WHO FC" exact="World Health Organization" post="functional class WSPH World Symposium on Pulmonary Hypertension 1"/>
  <result pre="coincidental CHD; postoperative PAH). 26 Other predictors of survival include" exact="World Health Organization" post="functional class (WHO FC), BNP/NT‐proBNP, mean right atrial pressure,"/>
  <result pre="avoid use of the high dose. By contrast the US" exact="Food and Drug Administration" post="(FDA) released a strong warning in August 2012 against"/>
  <result pre="pediatric patients. CONFLICTS OF INTEREST MB is a Consultant for" exact="Actelion Pharmaceuticals," post="Arena, Bayer AG, GlaxoSmithKline, Eli Lilly, and Pfizer; and"/>
  <result pre="OF INTEREST MB is a Consultant for Actelion Pharmaceuticals, Arena," exact="Bayer" post="AG, GlaxoSmithKline, Eli Lilly, and Pfizer; and has received"/>
  <result pre="and Pfizer; and has received grant support from Actelion and" exact="Bayer" post="AG, and personal fees from Actelion Pharmaceuticals, Arena, GlaxoSmithKline,"/>
  <result pre="support from Actelion and Bayer AG, and personal fees from" exact="Actelion Pharmaceuticals," post="Arena, GlaxoSmithKline, Eli Lilly, Pfizer, and Bayer Healthcare. The"/>
  <result pre="fees from Actelion Pharmaceuticals, Arena, GlaxoSmithKline, Eli Lilly, Pfizer, and" exact="Bayer" post="Healthcare. The University of Colorado receives fees for DDI"/>
  <result pre="to be a consultant for and perform research studies for" exact="Actelion Pharmaceuticals," post="Bayer AG, Eli Lilly, and United Therapeutics. DDI receives"/>
  <result pre="a consultant for and perform research studies for Actelion Pharmaceuticals," exact="Bayer" post="AG, Eli Lilly, and United Therapeutics. DDI receives grant"/>
  <result pre="Lilly, and United Therapeutics. DDI receives grant funding from the" exact="National Institutes of Health" post="and the FDA. DB is a consultant or steering"/>
  <result pre="FDA. DB is a consultant or steering committee member for" exact="Actelion Pharmaceuticals," post="Bayer AG, Novartis, and Eli Lilly. MG serves on"/>
  <result pre="is a consultant or steering committee member for Actelion Pharmaceuticals," exact="Bayer" post="AG, Novartis, and Eli Lilly. MG serves on an"/>
  <result pre="and Eli Lilly. MG serves on an advisory board for" exact="Bayer" post="AG and receives lecture fees: from Pfizer, MSD, and"/>
  <result pre="Bayer AG and receives lecture fees: from Pfizer, MSD, and" exact="Actelion Pharmaceuticals." post="SM serves on advisory boards or steering committees for"/>
  <result pre="Pharmaceuticals. SM serves on advisory boards or steering committees for" exact="Bayer" post="AG and Actelion Pharmaceuticals. ACKNOWLEDGMENTS Funding for the PATENT‐CHILD"/>
  <result pre="on advisory boards or steering committees for Bayer AG and" exact="Actelion Pharmaceuticals." post="ACKNOWLEDGMENTS Funding for the PATENT‐CHILD study was provided by"/>
  <result pre="Pharmaceuticals. ACKNOWLEDGMENTS Funding for the PATENT‐CHILD study was provided by" exact="Bayer" post="AG, Berlin, Germany and Merck Sharp &amp;amp; Dohme Corp.,"/>
  <result pre="PATENT‐CHILD study was provided by Bayer AG, Berlin, Germany and" exact="Merck" post="Sharp &amp;amp; Dohme Corp., a subsidiary of Merck &amp;amp;"/>
  <result pre="Germany and Merck Sharp &amp;amp; Dohme Corp., a subsidiary of" exact="Merck" post="&amp;amp; Co., Inc., Kenilworth, NJ, USA. Medical writing support"/>
  <result pre="accordance with Good Publication Practice (GPP3) guidelines and funded by" exact="Bayer" post="AG (Muellerstrasse 178, 13342 Berlin, Germany). References References REFERENCES"/>
  <result pre="Hypertension of the European Society of Cardiology (ESC) and the" exact="European Respiratory Society" post="(ERS): endorsed by: Association for European Paediatric and Congenital"/>
  <result pre="endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC)," exact="International Society for Heart and Lung Transplantation" post="(ISHLT) . Eur Respir J. 2015; 46: 903‐ 975."/>
 </snippets>
</snippetsTree>
